.
MergerLinks Header Logo

Announced

Completed

Bio-Techne completed the acquisition of a 20% stake in Wilson Wolf for $257m.

Financials

Edit Data
Transaction Value£212m
Consideration TypeCash
Capital Owned-
Capital Bid For20%
EV/Sales-
EV/EBITDA23.36x
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Friendly

Completed

Acquisition

Electronic Components and Equipment

culture technologies

United States

Minority

Domestic

Private

Synopsis

Edit

Bio-Techne, a life sciences company, completed the acquisition of a 20% stake in Wilson Wolf, a developer and manufacturer of cell culture technologies, for $257m. "This investment represents a great step toward our eventual full ownership of Wilson Wolf. The acquisition of Wilson Wolf, combined with our world-renowned portfolio of cell and gene therapy workflow solutions, caps 5 years of strategic investment to position Bio-Techne as a leader in tools serving this market. I am excited about Wilson Wolf's role in simplifying and reducing the cost of manufacturing cell therapies. Wilson Wolf has been a great partner in our ongoing collaboration through ScaleReady, and we are looking forward to further strengthening the relationship upon the achievement of the remaining milestone," Chuck Kummeth, Bio-Techne President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US